What the 2026 FDA CDS guidance covers (and what it doesn’t) The FDA’s January 2026 update to its Clinical Decision Support (CDS) guidance is not
TEFCA basics The Trusted Exchange Framework and Common Agreement (TEFCA) is the U.S. government’s attempt to create a nationwide, interoperable floor for health information exchange.
Introduction: The CKD Polypharmacy Burden Chronic kidney disease (CKD) often demands complex medication regimens. Patients commonly take losartan, metformin, SGLT2 inhibitors, and additional agents for
Digital Weight Management Platforms + Ozempic: Behavioural ‘Glue’ for GLP-1 Success Introduction: Why Lifestyle Support Still Matters The success of semaglutide-based therapies like Ozempic in
Gene therapy has already proven to be a fairly effective and safe method of treating many diseases, but remains inaccessible for widespread use in medical
This article succinctly describes the comparative disadvantages for healthcare startups in digital and connected health operating under the U.K.’s National Health Service compared with the
The U.S. Food and Drug Administration (FDA) plans to exempt 120 medical device classes from its premarket notification and review requirements, making it substantially easier
WLSA’s Rob McCray and Molly Cogan served on the selecting committee for this year’s San Diego MetroConnect Prize, presented by JP Morgan Chase & Co.
Wow!! It looking like 2015 will be another successful year for digital and connected health investments. We will see great technologies emerge in the healthcare
By Scott Donahue and Spencer Evenson “TripleTree has been evangelizing Connected Health’s impact in the broader healthcare landscape for years. We continue to use our sponsorship of the WLSA and
© 2026 Wireless-Life Sciences Alliance. All rights reserved.